NEW YORK (GenomeWeb) – Epigenomics and BioChain today announced the Epi proColon colorectal cancer detection test has been approved for marketing by regulators in China. 

The approval from the China Food and Drug Administration follows the completion of a clinical validation study by BioChain earlier this year that found the non-invasive blood-based test detected 75 percent of all cancer cases at 97.5 percent specificity. BioChain anticipates launching the test in the next few weeks through its distribution channels. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

 Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.

UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.

The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.